Top

Published in:

Open Access 01-12-2020 | Obesity | Research article

Associations between circulating resistin concentrations and left ventricular mass are not accounted for by effects on aortic stiffness or renal dysfunction

Authors: Glenda Norman, Gavin R. Norton, Vernice Peterson, Monica Gomes, Carlos D. Libhaber, Pinhas Sareli, Angela J. Woodiwiss

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Abstract

Background

Although, in-part through an impact on left ventricular mass (LVM), resistin (an adipokine) may contribute to heart failure, whether this is explained by the adverse effects of resistin on aortic stiffness and renal function is unknown.

Methods

Relationships between circulating resistin concentrations and LVM index (LVMI), and LVM beyond that predicted by stroke work (inappropriate LVM [LVM_inappr]) (echocardiography) were determined in 647 randomly selected community participants, and in regression analysis, the extent to which these relations could be explained by aortic pulse wave velocity (PWV) or estimated glomerular filtration rate (eGFR) was evaluated.

Results

Independent of confounders, resistin concentrations were independently associated with LVMI, LVM_inappr, LV hypertrophy (LVH), PWV and eGFR. Furthermore, independent of confounders, LVMI, LVM_inappr and LVH were independently associated with PWV and eGFR. However, adjustments for either PWV or eGFR failed to modify the relationships between resistin concentrations and LVMI, LVM_inappr or LVH. Moreover, in multivariate regression analysis neither PWV nor eGFR significantly modified the contribution of resistin to LVM_inappr or LVMI.

Conclusions

Independent relationships between circulating concentrations of the adipocytokine resistin and LVM are not explained by the impact of resistin on ventricular-vascular coupling or renal dysfunction. Resistin’s effects on LVM are therefore likely to be through direct actions on the myocardium.

Available only for authorised users

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. New Engl J Med. 2002;347:305–13. https://doi.org/10.1056/NEJMoa020245.CrossRefPubMed

Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334–41. https://doi.org/10.1001/jama.294.3.334.CrossRefPubMed

Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol. 2008;51:1775–83. https://doi.org/10.1016/j.jacc.2007.12.048.CrossRefPubMed

Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472–6. https://doi.org/10.1016/S0006-291X(02)02841-3.CrossRefPubMed

Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett. 2002;530:58–162. https://doi.org/10.1016/S0014-5793(02)03450-6.CrossRef

Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Comm. 2003;309:286–90. https://doi.org/10.1016/j.bbrc.2003.07.003.CrossRefPubMed

Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL, et al. For the health ABC study. Serum resistin concentrations and risk of new onset heart failure in older persons. The health, aging and body composition (health ABC) study. Arterioscler Thromb Vasc Biol. 2009;29:1144–9. https://doi.org/10.1161/ATVBAHA.109.186783.CrossRefPubMedPubMedCentral

Frankel DS, Vasan RS, D’Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, et al. Resistin, adiponection, and risk of heart failure: the Framingham heart study. J Am Coll Cardiol. 2009;53:754–62. https://doi.org/10.1016/j.jacc.2008.07.073.CrossRefPubMed

Zhang MH, Na B, Schiller NB, Whooley MA. Associations of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Cardiac Fail. 2011;17:24–30. https://doi.org/10.1016/j.cardfail.2010.08.007.CrossRef

10.

Wu X-M, Lin Y-H, Chen A, Hsu T-P, Wu Y-W, Lin H-J, et al. Prognostic significance of adipocytokines in systolic heart failure patients. Eur J Clin Investig. 2012;42:1079–86. https://doi.org/10.1111/j.1365-2362.2012.02698.x.CrossRef

11.

Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J. 2007;71:460–4. https://doi.org/10.1253/circj.71.460.CrossRefPubMed

12.

Muse ED, Feldman DI, Blaha MJ, Dardari ZA, Blumenthal RS, Budoff MJ, et al. The association of resistin with cardiovascular disease in the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;239:101–8. https://doi.org/10.1016/j.atherosclerosis.2014.12.044.CrossRefPubMed

13.

Norman G, Norton GR, Libhaber CD, Michel F, Majane OHI, Millen AME, et al. Independent associations between resistin and left ventricular mass and myocardial dysfunction in a community sample with prevalent obesity. Int J Cardiol. 2015;196:81–7. https://doi.org/10.1016/j.ijcard.2015.05.184.CrossRefPubMed

14.

Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45:270–80. https://doi.org/10.1016/j.yjmcc.2008.05.006.CrossRefPubMedPubMedCentral

15.

Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144–55. https://doi.org/10.1016/j.yjmcc.2011.04.006.CrossRefPubMedPubMedCentral

16.

Kang S, Chemaly ER, Hajja RJ, Lebeche D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMP K/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem. 2011;286:18465–73. https://doi.org/10.1074/jbc.M110.200022.CrossRefPubMedPubMedCentral

17.

Schwartz DR, Briggs ER, Qatanani M, Sawaya H, Sebag IA, Picard MH, et al. Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer. Endocrinology. 2013;154:4206–14. https://doi.org/10.1210/en.2013-1399.CrossRefPubMedPubMedCentral

18.

Mills KT, Hamm LL, Alper AB, Miller C, Hudaihed A, Balamuthusamy S, et al. Circulating adipocytokines and chronic kidney disease. PLoS One. 2013;8:e76902. https://doi.org/10.1371/journal.pone.0076902.CrossRefPubMedPubMedCentral

19.

Maunganidze F, Norton GR, Maseko MJ, Libhaber CD, Majane OHI, Sareli P, et al. Relationship between glomerular dysfunction and left ventricular mass independent of haemodynamic factors in a community sample. J Hypertens. 2013;31:568–75. https://doi.org/10.1097/HJH.0b013e32835cd607.CrossRefPubMed

20.

Norman G, Norton GR, Gomes M, Michel F, Majane OH, Sareli P, et al. Circulating resistin concentrations are independently associated with aortic pulse wave velocity in a community sample. J Hypertens. 2016;34:274–81. https://doi.org/10.1097/HJH.0000000000000792.CrossRefPubMed

21.

Bello H, Norton GR, Ballim I, Libhaber CD, Sareli P, Woodiwiss AJ. Contributions of aortic pulse wave velocity and backward wave pressure to variations in left ventricular mass are independent of each other. J Am Soc Hypertens. 2017;11:265–74. https://doi.org/10.1016/j.jash.2017.03.001.CrossRefPubMed

22.

Zanoli L, Di Pino A, Terranova V, Di Marca S, Pisano M, Di Quattro R, et al. Inflammation and ventricular-vascular coupling in hypertensive patients with metabolic syndrome. Nut Metab Cardiovasc Dis. 2018;28:1222–9. https://doi.org/10.1016/j.numecd.2018.08.003.CrossRef

23.

Norton GR, Majane OH, Maseko MJ, Libhaber C, Redelinghuys M, Kruger D, et al. Brachial blood pressure-independent relations between radial late systolic shoulder-derived aortic pressures and target organ changes. Hypertension. 2012;59:885–92. https://doi.org/10.1161/HYPERTENSIONAHA.111.187062.CrossRefPubMed

24.

Woodiwiss AJ, Molebatsi N, Maseko MJ, Libhaber E, Libhaber C, Majane OHI, et al. Nurse-recorded auscultatory blood pressure at a single visit predicts target organ changes as well as ambulatory blood pressure. J Hypertens. 2009;27:287–97. https://doi.org/10.1097/HJH.0b013e328317a78f.CrossRefPubMed

25.

Kolkenbeck-Ruh A, Woodiwiss AJ, Naran R, Sadiq E, Robinson C, Motau TH, et al. Carotid intima-media thickness, but not chronic kidney disease independently associates with non-cardiac arterial vascular events in South Africa. J Hypertens. 2019;37(4):795–804. https://doi.org/10.1097/HJH.0000000000001921.CrossRefPubMed

26.

Woodiwiss AJ, Libhaber CD, Libhaber E, Sareli P, Norton GR. Relationship between on-treatment decreases in inappropriate versus absolute or indexed left ventricular mass and increases in ejection fraction in hypertension. Hypertension. 2012;60:810–7. https://doi.org/10.1161/HYPERTENSIONAHA.112.197822.CrossRefPubMed

27.

Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiograph assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8. https://doi.org/10.1016/0002-9149(86)90771-X.CrossRefPubMed

28.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339.CrossRefPubMed

29.

Bell V, Sigurdsson S, Westenberg JJ, Gotal JD, Torjessen AA, Aspelund T, et al. Relations between aortic stiffness and left ventricular structure and function in older participants in the age/gene/environment susceptibility-Reykjavok study. Circ Cardiovasc Imaging. 2015;8:e003039. https://doi.org/10.1161/CIRCIMAGING.114.003039.CrossRefPubMedPubMedCentral

30.

Norton GR, Peterson VR, Robinson C, Norman G, Libhaber CD, Libhaber E, et al. Independent of left ventricular mass, circulating inflammatory markers rather than pressure load are associated with concentric left ventricular remodelling. Int J Cardiol. 2019;274:342–7. https://doi.org/10.1016/j.ijcard.2018.09.059.CrossRefPubMed

31.

Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199–202. https://doi.org/10.2337/diabetes.50.10.2199.CrossRefPubMed

Title: Associations between circulating resistin concentrations and left ventricular mass are not accounted for by effects on aortic stiffness or renal dysfunction
Authors: Glenda Norman
Gavin R. Norton
Vernice Peterson
Monica Gomes
Carlos D. Libhaber
Pinhas Sareli
Angela J. Woodiwiss
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Obesity
Obesity
Published in: BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-019-01319-w

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Associations between circulating resistin concentrations and left ventricular mass are not accounted for by effects on aortic stiffness or renal dysfunction

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Predictive capacity of obesity indices for high blood pressure among southern Ethiopian adult population: a WHO STEPS survey

Alternate recurrent coronary artery spasm and stress cardiomyopathy: a case report

Adverse clinical events caused by pacemaker battery depletion: two case reports

Proteomic analysis reveals sex-specific biomarker signature in postural orthostatic tachycardia syndrome

Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial

The diagonal branches and outcomes in patients with anterior ST- elevation myocardial infarction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page